## **SUPPLEMENTARY FIGURES**





Α	Standard chemo- therapeutic agents																
	0.58 (0.39, 0.80)	B-containing regimens															
	0.41 (0.29, 0.55)	0.71 (0.46, 1.11)	P-containing regimens														
	0.32 (0.18, 0.53)	0.55 (0.34, 0.90)	0.78 (0.44, 1.3	(6) B	P-containi gimens	ng											
	1.28 (0.44, 3.51)	2.24 (0.74, 6.64)	3.17 (1.06, 9.0	1) 4	.03 (1.25,	12.44)	Pi-contai regimens	ning									
	0.42 (0.23, 0.68) 0.72 (0.38, 1.34) 1.03 (0.58, 1.73)		3)	1.30 (0.62, 2.68)		0.32 (0.10, 1.03)		PPi-co regime	PPi-containing regimens								
	0.83 (0.38, 1.87)	1.45 (0.60, 3.58)	2.05 (0.87, 5.0	0)	2.65 (1.01, 7.07)		0.66 (0.18, 2.59)		2.02 (0.80, 5.48)		) Ca reg	Ca-containing regimens		o			
	0.91 (0.50, 1.59)	1.57 (0.82, 3.12)	2.23 (1.28, 3.9	49	2.85 (1.35, 6.15)		0.71 (0.22, 2.39)		2.18	2.18 (1.06, 4.73)		1.09 (0.39, 3.01)		regimens	ning	PE containing	1
	0.67 (0.26, 1.69)	1.16 (0.44, 3.15)	1.63 (0.69, 4.0	0)	2.11 (0.74, 5.99)		0.52 (0.13, 2.14)		1.62 (0.58, 4.60)		9 0.	0.81 (0.23, 2.65)		0.73 (0.26	, 2.12)	regimens	E-containing
	0.82 (0.21, 3.16)	1.43 (0.35, 5.85)	2.04 (0.48, 8.3	0)	1.56 (0.57,	11.05)	0.65 (0.1	12, 3.75)	1.95	(0.47, 8.61	) 0.	98 (0.20, 4.	75)	0.90 (0.19	, 4.05)	1.20 (0.24, 6.62)	regimens
R																	
D	Standard ch	nemotherapeti	c agents	0	0	0	0	0.01	0.06	0.22	0.37	0.27	0.06			0.6	
		B-containing r	egimens	0	0.02	0.07	0.30	0.35	0.19	0.06	0.01	0	0				
		P-containing r	egimens	0.08	0.36	0.37	0.16	0.03	0	0	0	0	0			0.4	
	В	P-containing r	regimens	0.64	0.20	0.10	0.04	0.01	0	0	0	0	0				
	F	Pi-containing r	regimens	0.01	0.01	0.01	0.02	0.04	0.07	0.09	0.10	0.18	0.47			0.2	
	PF	Pi-containing r	egimens	0.13	0.27	0.30	0.17	0.09	0.03	0.01	0	0	0				
	С	a-containing r	egimens	0.01	0.02	0.04	0.07	0.12	0.18	0.17	0.15	0.14	0.10	-		2	
	G	e-containing r	egimens	0	0	0.01	0.02	0.07	0.19	0.23	0.20	0.18	0.09	_	Rank	u probability	
	Р	E-containing r	egimens	0.04	0.05	0.07	0.14	0.17	0.17	0.13	0.09	0.08	0.06				
		E-containing r	egimens	0.09	0.07	0.05	0.07	0.10	0.10	0.09	0.08	0.14	0.21				
			R2	NY P	ant Ps	ant P	ant P3	NH -3 P.8	et P3	ant P3	NY P	ant Rai	4/2				
				Best								<b>`</b>	Wor	rst			

Supplementary Figure 2. Subgroup Bayesian network meta-analysis for pathologic complete response (pCR). (A) The league table of comparisons. Data are presented as odds radio (OR) and 95% confidence intervals (CI). An OR>1 favors the column-defining treatment, and OR <1 favors the row-defining treatment. (B) Heatmap of the rank probability of the regimens for pCR. Rank 1 represents the best treatment and rank 10 represents the worst. Rank probabilities sum to one, both within a rank over treatments and within a treatment over ranks.



## Supplementary Figure 3. Network diagram of eligible comparisons included in the network meta-analysis for serious adverse

**events.** (A) Network diagram of eligible comparisons for anemia. (B) Network diagram of eligible comparisons for neutropenia. (C) Network diagram of eligible comparisons for thrombocytopenia. The node size is proportional to the total number of patients in the regimen. The width of each line is proportional to the number of studies comparing the two regimens linked by the line. B, bevacizumab; P, platinum salts; BP, bevacizumab plus platinum salts; Pi, Poly (ADP-ribose) polymerases inhibitors; PPi, platinum salts plus Poly (ADP-ribose) polymerases inhibitors; Ca, capecitabine; Ge, gemcitabine; Za, zoledronic acid; E, everolimus; PE, platinum salts plus everolimus; G, gefitinib.

Λ								
А		Standard chemotherapeutic a	igents	P-containing reg	imens		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
	Alba 2012	5	47	0	46	8.9%	12.04 [0.65, 224.22]	
	Ando 2014	17	88	1	91	15.8%	21.55 [2.80, 165.83]	<b>→</b>
	Loibl 2018	27	158	0	157	8.3%	65.87 [3.98, 1090.30]	
	Sikov 2015	4	111	0	107	9.7%	9.00 (0.48, 169.22)	• • •
	Wu 2018	32	61	6	60	57.3%	9.93 [3.72, 26,51]	
	Total (95% CI)		465		461	100.0%	16.49 [7.52, 36, 14]	
	Total events	85	100	7		1001070	10110 [1102, 00111]	
	Hotorogeneity: Chi2 -	2 22 df = 4 (P = 0.60); P = 0%		,				· · · · · · · · · · · · · · · · · · ·
	Tect for overall effect:	2.23, ul = 4 (F = 0.03), l = 0.00 (F = 0.03), l = 0.00 (F < 0.00001)						0.01 0.1 i 10 100
	restion overall ellect.	2 = 7.00 (F < 0.00001)					Favo	ours [Standard chemotherapeutic agents] Favours [P-containing regimens]
R								
		Standard chemotherapeutic a	igents	P-containing reg	imens		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
	Alba 2012	8	47	10	46	15.5%	0.74 [0.26, 2.08]	
	Ando 2014	58	88	35	91	17.9%	3.09 [1.68, 5.70]	
	Loibl 2018	84	158	4	157	15.4%	43.42 [15.34, 122.93]	<b>_</b>
	Sikov 2015	62	111	24	107	18.0%	4.38 [2.43, 7.88]	
	Wu 2018	24	61	14	60	16.9%	213 [0 97 4 69]	
	7hang 2016	34	47	28	44	16.4%	1 49 [0 62 3 63]	
	2000 2010	01		20		10.170	1.10 [0.02, 0.00]	
	Total (95% CI)		512		505	100.0%	3.30 [1.35, 8.08]	
	Total events	270	012	115			0.00 [ 1.00, 0.00]	
	Heterogeneity: Tau <sup>2</sup> =	1 07: Chi² = 38 72 df = 5 (P < 0.	00001\-1	Z= 87%				
	Tect for overall effect:	7 = 2.62 (P = 0.009)	00001),1	- 07 /0				0.01 0.1 1 10 100
	restion overall ellect.	2 = 2.02 (1 = 0.003)					Fav	ours [Standard chemotherapeutic agents] Favours [P-containing regimens]
C								
U		Standard chemotherapeutic	agents	B-containing re	gimens		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Tota	Events	Tota	l Weigh	t M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
	Earl 2015	168	384	146	391	34.49	5 1.31 [0.98, 1.74]	
	Gerber 2013	763	938	3 747	939	58.29	1.13 [0.90, 1.43]	+
	Sikov 2015	28	105	i 24	107	7 4 9	1 26 (0.67, 2.35)	
	Total (95% CI)		1425	i	4427			
	Total events	959			1437	100.0%	1.20 [1.01, 1.43]	◆
	Heterogeneity Chi <sup>2</sup> =			917	1457	100.0%	1.20 [1.01, 1.43]	•
	Heterogeneity. Ohr =	$0.59 \text{ df} = 2 (P = 0.75) \cdot P = 0.96$		917	1457	100.0%	1.20 [1.01, 1.43]	► F F F F F F F F F F F F F F F F F F F
	Test for overall effect	= 0.59, df = 2 (P = 0.75); l <sup>2</sup> = 0%		917	1437	100.0%	1.20 [1.01, 1.43]	↓ 0.01 0.1 1 10 100
	Test for overall effect	= 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04)		917	1437	100.0%	6 <b>1.20 [1.01, 1.43]</b> Favor	0.01 0.1 1 1 10 100 urs (Standard chemotherapeutic agents) Favours (B-containing regimens)
	Test for overall effect	= 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04)		917	1437	100.0%	5 <b>1.20 [1.01, 1.43]</b> Favor	0.01 0.1 10 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens]
	Test for overall effect	: 0.59, df = 2 (P = 0.75); i² = 0% : Z = 2.09 (P = 0.04)		917	1437	100.0%	5 <b>1.20 [1.01, 1.43]</b> Favor	0.01 0.1 1 10 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens]
П	Test for overall effect	: 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04)		917	1437	100.0%	5 <b>1.20 [1.01, 1.43]</b> Favor	0.01 0.1 10 100 Urs [Standard chemotherapeutic agents] Favours [B-containing regimens]
D	Test for overall effect	0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic	agents	917 P-containing re	gimens	100.09	6 1.20 [1.01, 1.43] Favor Odds Ratio	0.01 0.1 1 1 10 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens] Odds Ratio
D	Test for overall effect	: 0.59, df= 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events	agents Tota	917 P-containing re Events	gimens Tota	100.0%	6 1.20 [1.01, 1.43] Favor Odds Ratio	0.01 0.1 1 1 0 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens] Odds Ratio M-H, Fixed, 95% CI
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012	: 0.59, df = 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3	agents Tota 47	917 P-containing re <u>Events</u> 0	gimens Total	100.0%	<ul> <li>1.20 [1.01, 1.43]</li> <li>Favor</li> <li>Odds Ratio</li> <li>M-H, Fixed, 95% CI</li> <li>7.31 [0.37, 145,68]</li> </ul>	0.01 0.1 1 10 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens] Odds Ratio M-H, Fixed, 95% Cl
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014	: 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 1	agents Tota 47 88	917 P-containing re <u>Events</u> 0	gimens <u>Total</u> 91	100.0%	Odds Ratio           M.H. Fixed, 95% CI           7.31 (0.37, 145.68)           3.14 / 10.13, 78.051	Odds Ratio
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014 Loibl 2018	: 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10	agents Total 47 88 158	917 P-containing re <u>Events</u> 0 3 0	gimens Tota 91 157	Weight 8.3% 8.5%	Odds Ratio           M.H. Fixed, 95% CI           7.31 [0.37, 145.68]           3.14 [0.13, 78.05]           22.27 [1.9, 383.46]	0.01 0.1 10 100 urs [Standard chemotherapeutic agents] Favours [B-containing regimens] Odds Ratio M-H, Fixed, 95% Cl
D	Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikoy 2015	: 0.59, df = 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22	agents <u>Totai</u> 47 88 158 111	917 P-containing re Events 0 0 0 0 0	gimens <u>Tota</u> 91 157 107	Weight 8.3% 8.5% 8.3% 8.5%	Odds Ratio M.H. Fixed, 95% CI 7.31 [0.37, 145.68] 3.14 [0.13, 78.05] 22.27 [1.29, 383.46] 6.37 [21, 11, 19, 17]	Odds Ratio
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018	: 0.59, df = 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21	agents <u>Tota</u> 47 88 158 111 61	917 P-containing re Events 0 0 0 0 1	gimens Total 48 91 157 107 60	Weight 8.3% 8.5% 5.7.5% 11.6%	Odds Ratio M-H, Fixed, 95% CI 7.31 (0.37, 145.68) 3.14 (0.13, 78.05) 22.27 (1.29, 383.46) 6.37 (2.11, 19.17) 3.09 g/4 dn 279 621	Odds Ratio
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016	: 0.59, df= 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemother apeutic Events 3 1 10 22 21 17	agents Total 47 88 158 111 61	917  P-containing re  Events  0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0	gimens Total 46 91 157 107 60	Weight 8.3% 8.5% 57.5% 11.6%	Odds Ratio M.H. Fixed, 95% CI 7.31 [0.37, 145.68] 3.14 [0.13, 78.05] 9.22.77 [1.29, 383.46] 6.37 [2.11, 19.17] 30.98 [4.00, 239.62] 5.10 [7 09.881 [0.00, 881 [0.00]	0.01 0.1 1 1 10 100 urs (Standard chemotherapeutic agents) Favours (B-containing regimens) Odds Ratio
D	Test for overall effect Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016	: 0.59, df= 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21 17	agents Total 47 88 158 111 61 47	917  P-containing re Events 0 0 0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0	gimens <u>Total</u> 91 157 107 60 44	Weight 8.3% 8.5% 8.3% 57.5% 11.6%	Odds Ratio Favor Odds Ratio M.H. Fixed, 95% CI 7.31 [0.37, 145.68] 3.14 [0.13, 78.05] 22.27 [1.29, 383.46] 6.37 [2.11, 19.17] 30.98 [4.00, 239.62] 51.07 [2.96, 881.60]	Odds Ratio
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI)	: 0.59, df = 2 (P = 0.75); I <sup>2</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21 17	agents Tota 47 88 158 111 61 47	917  P-containing re  Events  0  0  0  4  1  0  0  0  0  0  0  0  0  0  0  0  0	gimens Total 91 157 107 60 44	Weight Weight 8.3% 8.5% 8.3% 57.5% 11.6% 5.8% 100.0%	Odds Ratio M-H, Fixed, 95% CI 7.31 (0.37, 145.68) 3.14 [0.13, 78.05] 22.27 [1.29, 383.46] 6.37 [2.11, 19.17] 30.98 [4.00, 239.62] 51.07 [2.36, 881.60] 51.07 [2.36, 881.60]	Odds Ratio
D	Test for overall effect <u>Study or Subgroup</u> Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI) Total compte	: 0.59, df = 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemother apeutic Events 3 1 10 22 21 17 74	agents Total 47 88 158 111 61 47 512	917  P-containing re  Events  0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0	gimens <u>Total</u> 46 91 157 107 60 44 505	Weight Weight 8.3% 8.5% 8.5% 57.5% 11.6% 58% 100.0%	Odds Ratio           M.H. Fixed, 95% CI           7.31 [0.37, 145.68]           3.14 [0.13, 78.05]           22.27 [1.29, 383.46]           6.37 [2.11, 19.17]           30.98 [4.00, 239.62]           51.07 [2.96, 881.60]           12.93 [5.91, 28.29]	Odds Ratio M-H, Fixed, 95% CI
D	Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI) Total events	20.59, df = 2 (P = 0.75); P = 0% Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21 17 74 74	agents Total 47 88 158 111 61 47 512	917 P-containing re P-containing re P-containing re 0 0 0 0 0 0 1 1 0 1 5 5	gimens Total 91 157 107 60 44 505	Weight Weight 3.3% 8.5% 8.5% 5.5% 11.6% 5.8% 100.0%	Odds Ratio           H. Fixed, 95% CI           7.31 [0.37, 145.68]           3.14 [0.13, 78.05]           22.27 [1.29, 383.46]           6.37 [2.11, 19.17]           30.88 [4.00, 239.62]           51.07 [2.96, 881.60]           12.93 [5.91, 28.29]	Odds Ratio
D	Test for overall effect Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI) Total events Heterogeneity: Chi <sup>™</sup> = Total (25% CI)	= 0.59, df = 2 (P = 0.75); P = 0% Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21 17 74 = 4.21, df = 5 (P = 0.52); P = 0% T = 0.52); P = 0%	agents Total 47 88 158 111 61 47 512	917  P-containing re  Events  0 0 0 0 0 4 1 0 0 2 5	gimens Total 46 91 157 107 60 44 505	Weight Weight 3 8.3% 8.5% 8.3% 57.5% 11.6% 5.8% 100.0%	M.H. Fixed, 95% CI           7.31 [0.37, 145.68]           3.14 [0.13, 78.05]           22.27 [1.29, 383.46]           6.37 [2.11, 19.17]           30.98 [4.00, 239.62]           51.07 [2.96, 881.60]           12.93 [5.91, 28.29]	Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 10 100 0.01 0.1 10 100
D	Test for overall effect Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect	= 0.59, df = 2 (P = 0.75); I <sup>P</sup> = 0% : Z = 2.09 (P = 0.04) Standard chemother apeutic Events 3 1 10 22 21 17 : 4.21, df = 5 (P = 0.52); I <sup>P</sup> = 0% : Z = 6.41 (P < 0.00001)	agents Total 47 88 158 1111 61 47 512	917  P-containing re  Events  0 0 0 0 4 1 1 0 2 5	gimens <u>Total</u> 46 91 157 107 60 44 505	Weight Weight 8.3% 8.5% 8.3% 57.5% 11.6% 5.8% 100.0%	Odds Ratio           M.H. Fixed, 95% CI           7.31 [0.37, 145.68]           3.14 [0.13, 78.05]           22.27 [1.29, 383.46]           6.37 [2.11, 19.17]           30.98 [4.00, 239.62]           51.07 [2.96, 881.60]           12.93 [5.91, 28.29]	Odds Ratio 0.01 0.1 1 1 0 100 Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 10 100 0.01 0.1 10 100 Favours [B-containing regimens]
D	Test for overall effect Study or Subgroup Alba 2012 Ando 2014 Loibl 2018 Sikov 2015 Wu 2018 Zhang 2016 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect	= 0.59, df = 2 (P = 0.75); P = 0% : Z = 2.09 (P = 0.04) Standard chemotherapeutic Events 3 1 10 22 21 17 : 4.21, df = 5 (P = 0.52); P = 0% : Z = 6.41 (P < 0.00001)	agents Total 47 88 158 111 61 47 512	917  P-containing re Events  0 0 0 0 0 1 1 0 0 0 5 0 0 0 0 0 0 0 0	gimens <u>Total</u> 46 91 157 107 60 44 505	Weight Weight 8.3% 8.3% 8.3% 5.5% 5.8% 11.6% 100.0%	Odds Ratio           0.1.20 [1.01, 1.43]           Favor           0.1.1 (0.13, 145.68)           3.14 [0.13, 78.05]           22.27 [1.29, 383.46]           3.0.38 [4.00, 239.62]           51.07 [2.96, 881.60]           12.93 [5.91, 28.29]	Odds Ratio Odds Ratio M-H_Fixed, 95% CI 0.01 0.1 10 100 0.01 0.1 10 100 0.01 0.1 10 100 0.01 0.1 10 100 0.01 100 0.00 100 0

Supplementary Figure 4. Pairwise meta-analyses of serious adverse events. (A) Forest plot for anemia. Standard chemotherapeutic agents vs. P-containing regimens. (B) Forest plot for neutropenia. Standard chemotherapeutic agents vs. P-containing regimens. (C) Forest plot for neutropenia. Standard chemotherapeutic agents vs. B-containing regimens. (D) Forest plot for thrombocytopenia. Standard chemotherapeutic agents vs. P-containing regimens.

Δ								
~		Standard chemotherapeutic	agents	P-containing re	egimens		Odds Ratio	Odds Ratio
1	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
	Alba 2012	5	47	0	46	10.6%	12.04 [0.65, 224.22]	
	Loibl 2018	27	158	0	157	9.8%	65.87 [3.98, 1090.30]	· · · · · · · · · · · · · · · · · · ·
	Sikov 2015	4	111	0	107	11.6%	9.00 [0.48, 169.22]	
	Wu 2018	32	61	6	60	68.0%	9.93 [3.72, 26.51]	
	Total (95% CI)		377		370	100.0%	15.54 [6.64, 36.34]	•
	Total events	68		6				
	Heterogeneity: Chi <sup>2</sup> =	1.98, df = 3 (P = 0.58); I <sup>2</sup> = 0%						
	Test for overall effect:	Z = 6.33 (P < 0.00001)					Favo	urs [Standard chemotherapeutic agents] Favours [P-containing regimens]
в								
		Standard chemotherapeutic	agents	P-containing re	egimens		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
	Alba 2012	8	47	10	46	19.2%	0.74 [0.26, 2.08]	
	Loibl 2018	84	158	4	157	19.1%	43.42 [15.34, 122.93]	<b>_</b>
	Sikov 2015	62	111	24	107	21.3%	4.38 [2.43, 7.88]	
	Wu 2018	24	61	14	60	20.4%	2.13 [0.97, 4.69]	
	Zhang 2016	34	47	28	44	20.0%	1.49 [0.62, 3.63]	
	Total (95% CI)		424		414	100.0%	3.36 [1.04, 10.83]	
	Total events	212		80				
	Heterogeneity: Tau <sup>2</sup> =	= 1.58; Chi <sup>2</sup> = 38.95, df = 4 (P < 0	).00001); l²	= 90%				
	Test for overall effect:	Z = 2.03 (P = 0.04)					Fave	ours [Standard chemotherapeutic agents] Favours [P-containing regimens]
~								
C		Standard chemotherapeutic	agents	P-containing r	eaimens		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Total	Events	Tota	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
	Alba 2012	3	47	0	46	9.0%	7 31 /0 37 145 681	
	Loibl 2018	10	158	ů.	157	9.0%	22 27 [1 29 383 46]	
	Sikov 2015	22	111	4	107	62.9%	6 37 [2 11 19 17]	
	VA01 2018	21	61	1	60	12.7%	30 98 14 00 239 621	
	Zhang 2016	17	47	0	44	6.3%	51.07 [2.96, 881.60]	
	Total (95% CI)		424		414	100.0%	13.84 [6.14, 31.20]	
	Total events	73		5				
	Heterogeneity: Chi <sup>2</sup> =	3.59. df = 4 (P = 0.46); I <sup>2</sup> = 0%		•				
	Test for overall effect	Z = 6.34 (P < 0.00001)					Favo	0.01 0.1 1 1 10 100 ours [Standard chemotherapeutic agents] Favours [P-containing regimens]

Supplementary Figure 5. Subgroup pairwise meta-analyses of serious adverse events in TNBC patients. (A) Forest plot for anemia. (B) Forest plot for neutropenia. (C) Forest plot for thrombocytopenia. The three comparisons are standard chemotherapeutic agents vs. P-containing regimens.



Supplementary Figure 6. Funnel plots of the publication bias tests for direct comparisons of serious adverse events. (A) Funnel plot for anemia. (B) Funnel plot for neutropenia. (C) Funnel plot for thrombocytopenia. The three comparisons are standard chemotherapeutic agents vs. P-containing regimens.

Α



Supplementary Figure 7. Heatmaps of the rank probability of the regimens for serious adverse events. (A) Rank probability of anemia. (B) Rank probability of neutropenia. (C) Rank probability of thrombocytopenia. Rank 1 represents the worst treatment and rank N represents the best. Rank probabilities sum to one, both within a rank over treatments and within a treatment over ranks.



**Supplementary Figure 8. Central weights and confidence factor (CF) for each regimen.** (A) Analysis based on synthesizing pCR and anemia. (B) Analysis based on synthesizing pCR and neutropenia. (C) Analysis based on synthesizing pCR and thrombocytopenia. (D) Analysis based on synthesizing pCR and the three serious adverse events. The sum of the central weight for each intervention equals to one. A high central weight indicates that the intervention being considered is the best for that outcome. The confidence factor represents the probability of an intervention obtaining the first rank.